MIMETAS Participates in €325 Million Oncode-PACT Initiative to Accelerate and Improve Oncology Drug

LEIDEN, The Netherlands, April 19, 2022 / B3C newswire / -- MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in the Oncode-PACT (Preclinical Accelerator for Cancer Treatments) initiative that has been granted today an amount of €325 million by the Dutch National Growth Fund. Oncode Instit...

Related Keywords

United States ,Netherlands ,Holland ,Dutch ,Jos Joore ,Dutch Research Council ,Ministry Of Health ,Ministry Of Economic Affairs ,Drug Development ,Loncode Institute ,Dutch Cancer Society ,Dutch National Growth Fund ,Ministry Of Education ,Preclinical Accelerator ,Cancer Treatments ,Dutch National Growth ,Economic Affairs ,Climate Policy ,Capital Financing ,Biological Assay ,High Throughput Screening Assays ,Drug Discovery ,Drug Industry ,Early Detection ,Lab Ona Chip Devices ,Cell Culture Techniques ,Drug Evaluation ,